Please login to the form below

Not currently logged in
Email:
Password:

eribulin

This page shows the latest eribulin news and features for those working in and with pharma, biotech and healthcare.

Keytruda monotherapy fails in triple negative breast cancer

Keytruda monotherapy fails in triple negative breast cancer

By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine).

Latest news

  • AZ and Merck & Co get FDA breast cancer nod for Lynparza AZ and Merck & Co get FDA breast cancer nod for Lynparza

    In the OLYMPIAD trial, Lynparza achieved a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to standard chemotherapy (with capecitabine, vinorelbine or eribulin).

  • NICE set to reject wider use of Eisai’s Halaven NICE set to reject wider use of Eisai’s Halaven

    Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... According to the appraisal committee “it’s not clear

  • AZ's Lynparza shows PARP inhibitor potential in breast cancer AZ's Lynparza shows PARP inhibitor potential in breast cancer

    Lynparza (olaparib) significantly improved progression-free survival (PFS) in women with HER2-negative metastatic breast cancer with a germline BRCA mutation, when compared with standard therapy with capecitabine, vinorelbine or eribulin

  • AZ moves closer to Lynparza filing in breast cancer AZ moves closer to Lynparza filing in breast cancer

    Compared to standard chemotherapy with capecitabine, vinorelbine or eribulin, Lynparza achieved a "statistically-significant and clinically-meaningful" improvement in progression-free survival (PFS) in the OLYMPIAD trial, said the company, although

  • NICE backs Eisai's Halaven for breast cancer NICE backs Eisai's Halaven for breast cancer

    The UK health technology assessment agency has approved Halaven (eribulin) for routine treatment of patients with locally advanced or metastatic breast cancer that has spread after two prior chemotherapy regimens. ... metastatic breast cancer in England

More from news
Approximately 4 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics